Scleroderma and malignancy: an epidemiological study

Ann K Rosenthal, Joseph K McLaughlin, Martha S Linet, Ingemar Persson

Abstract

Objectives—Although case reports and some patient series suggest an increased risk of cancer among patients with scleroderma, there are no population based studies to support this association. A population based follow up study was therefore carried out of 233 patients with scleroderma from the six-county Uppsala health care region of Sweden for the time period 1955–84.

Methods—Using the inpatient registry for the Uppsala health care region, all patients with scleroderma were identified. Their unique identification codes were then used to perform a record linkage with the National Cancer Registry. Expected cancer rates were determined using the age and gender specific rates for the Uppsala health care region.

Results—The standardised incidence ratio (SIR) for all cancers among these patients was significantly increased (SIR=2.4; 95% CI=1.6 to 3.6). The SIRs for lung cancer (SIR=7.8; 95% CI=2.5 to 18.2) and non-Hodgkin's lymphoma (SIR=9.6; 95% CI=1.1 to 34.5) were also significantly increased. Excluding patients who were diagnosed with cancer within a year of their scleroderma diagnosis resulted in similar findings, though the SIR for non-Hodgkin's lymphoma was no longer statistically significant.

Conclusions—Larger population based investigations of cancer risk among patients with scleroderma are needed to confirm these initial findings and to evaluate in greater detail possible cancer risk among these patients.

We report herein the results of a population based study examining scleroderma and subsequent malignancy.

Subjects and methods

COHORT

The six county Uppsala health care region in central Sweden includes a population of 1.2–1.3 million. As almost no private inpatient treatment exists in Sweden, all hospital based care is recorded in the inpatient discharge registry, and in effect is population based. For the present analysis we used data from this registry for the years 1965–83, which included information on any operations performed, and up to eight discharge diagnoses. Diagnoses are coded according to the seventh revision of International Classification of Diseases (ICD) code up to 1968 and the eighth revision thereafter. Underreporting for the inpatient discharge registry is estimated at <2%.8

All computer records containing ICD codes for scleroderma were reviewed. For the ICD 7th revision, the codes used for scleroderma were 710-05 (28 patients) and 710-06 (eight patients); for the ICD 8th revision codes 734-00 (74 patients), 734-01 (36 patients), and 734-09 (87 patients) were included. Localised scleroderma and all overlap syndromes were excluded. Patients with incomplete registration numbers or invalid codes were also excluded (nine patients). The inpatient discharge registry has been used to examine a number of disease and subsequent cancer relations,9 10

FOLLOW UP

After identifying all eligible patients, each patient's unique 10 digit national registration number was used to perform a record linkage with the National Cancer Registry (to determine cancer incidence) and with the National Causes of Death Registry (to determine date of death). By law, all cancers must be reported to the National Cancer Registry, which has almost complete ascertainment.11 The time of observation was recorded as the registration date at the hospital for the first diagnosis of scleroderma to the time of cancer diagnosis, death, or the end of the observation period (31 December 1984).

STATISTICAL METHODS

We calculated the expected number of cancers by multiplying the number of patient years by the age and sex specific cancer rates for the Uppsala health care region provided by the National Cancer Registry. The distribution is
Table 1 Characteristics of patients with scleroderma in the Uppsala health care region (1965–83)

<table>
<thead>
<tr>
<th>Cancer site</th>
<th>Observed</th>
<th>Expected</th>
<th>SIR</th>
<th>95% Confidence interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>All cancers</td>
<td>22</td>
<td>9·27</td>
<td>2·4</td>
<td>1·5 to 3·6</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>5</td>
<td>0·64</td>
<td>7·9</td>
<td>2·5 to 18·2</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>2</td>
<td>1·19</td>
<td>1·7</td>
<td>0·2 to 6·1</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>1</td>
<td>0·28</td>
<td>3·6</td>
<td>0·1 to 19·9</td>
</tr>
<tr>
<td>Oesophageal cancer</td>
<td>0</td>
<td>0·09</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Lymphatic and haematopoietic</td>
<td>3</td>
<td>0·64</td>
<td>4·7</td>
<td>0·9 to 13·7</td>
</tr>
<tr>
<td>Non-Hodgkin’s lymphoma</td>
<td>2</td>
<td>0·20</td>
<td>9·6</td>
<td>1·1 to 34·5</td>
</tr>
</tbody>
</table>

Table 2 Standardised incidence ratios (SIR) of selected cancers among patients with scleroderma from the Uppsala health care region (1965–84)

Patients with scleroderma in this cohort did not have a significantly increased risk of breast, ovarian, or oesophageal cancers, though the power to detect excess risk for these tumours was limited.

Discussion

Several early studies concluded that there was no increase in malignancy among patients with scleroderma, but most of these were reports on the prevalence of cancer at initial presentation in tertiary referral centres or the prevalence of malignancies at necropsy among patients with scleroderma. The risk of cancer cannot be assessed in these studies because no appropriate comparison data were available to calculate rates. In one study in which risk was calculated, Black et al found no increased incidence of cancer among 27 patients with scleroderma from a single centre in Australia.

In contrast, Roumm and Medsger reported an increased risk for cancer of 1·8 among 262 patients with scleroderma from a tertiary care hospital in Pittsburgh compared with expected rates. This increase was largely accounted for by an increase in lung cancer (relative risk 4·4). Another follow up study, as well as prevalence and necropsy data, have suggested that the risk of lung cancer may be increased among patients with scleroderma. Our data support this association. Although alveolar cell carcinoma has been linked with scleroderma in clinical reports, squamous cell cancers predominated in our patients. Pulmonary fibrosis associated with scleroderma may increase the risk of lung cancer. Growth factors implicated in fibrosis may be mitogenic and cause excess cell division resulting in transformation. Alternatively, changes in the extracellular matrix, which plays an important part in growth and differentiation, may affect the behaviour of normal cells.

We observed a suggestive excess risk of non-Hodgkin’s lymphoma among patients with scleroderma. No increase of non-Hodgkin’s lymphoma was found in two earlier follow up studies of patients, nor has there been an excess of scleroderma been reported in case-control studies of non-Hodgkin’s lymphoma. Patients with other connective tissue disorders, however, notably rheumatoid arthritis and Sjögren’s syndrome, have shown an excess risk of non-Hodgkin’s lymphoma. Moreover, cases of non-Hodgkin’s lymphoma were described in a large series of patients with scleroderma referred to the Mayo Clinic and in a recent case report from France. It is possible that the increased risk of non-Hodgkin’s lymphoma among patients with scleroderma is due to the use of cytotoxic drugs.

Although patients with scleroderma have been reported with oesophageal cancer, particularly among those with Barrett’s syndrome, we observed none. Breast and ovarian cancers have been described in case reports and in a large series of patients with scleroderma. We did not observe any excess of breast cancer.
or ovarian cancers after the exclusion of the first year of follow up, but our statistical power to evaluate these associations was limited.

We evaluated selection bias in two ways in this study. First, we excluded all cancers occurring up to one year after the diagnosis of scleroderma to avoid those patients whose underlying cancer was a possible cause of admission to hospital. Second, we restricted the cohort to only those patients with scleroderma as their primary discharge diagnosis to assess Berkson's bias. Neither of these manoeuvres materially changed the results.

The advantages of this study include its population-based nature and the near complete coverage of the cancer registry and the patient discharge registry, which includes patients admitted to hospital anywhere in Sweden with scleroderma who lived in the Uppsala region during the study period. On the other hand, the patient cohort was relatively small and included only those patients with a hospital diagnosis. These patients may be older and have more severe scleroderma than patients not admitted to hospital. The average age at entry to the cohort, 57-9 years, suggests that the patients are older than the 45-54 year old age group which is the most common age group at time of diagnosis. The ratio of women to men in our cohort, 1:6:1, is lower than previously reported, but more in line with the sex ratios found among older patients. Despite these problems, we believe that this study can provide useful epidemiological clues.

In summary, we have observed an increased risk of lung cancer and a suggestive excess of non-Hodgkin's lymphoma in a cohort of patients with scleroderma. Larger studies are needed to confirm these findings and to evaluate other site specific cancers thought to be in excess among these patients.

Dr Rosenthal is a recipient of a postdoctoral fellowship from the Arthritis Foundation. We thank Mr Eric Berger of IMS, Inc. for computer support.


Table 3 Standardised incidence ratios (SIR) of selected cancers among patients with scleroderma from the Uppsala health care region (1965-84) excluding those occurring in the first year of follow up

<table>
<thead>
<tr>
<th>Cancer sites</th>
<th>Observed</th>
<th>Expected</th>
<th>SIR</th>
<th>95% Confidence interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>All cancers</td>
<td>16</td>
<td>7.95</td>
<td>2.02</td>
<td>1.2 to 3.3</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>44</td>
<td>0.54</td>
<td>8.11</td>
<td>5.0 to 12.8</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>1</td>
<td>1.01</td>
<td>1.00</td>
<td>0.0 to 5.5</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>0</td>
<td>0.24</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Esophageal cancer</td>
<td>0</td>
<td>0.07</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Lymphatic and haematopoietic cancers</td>
<td>2</td>
<td>0.55</td>
<td>3.7</td>
<td>4.0 to 13.3</td>
</tr>
<tr>
<td>Non-Hodgkin's lymphoma</td>
<td>1</td>
<td>0.18</td>
<td>5.6</td>
<td>0.1 to 31.1</td>
</tr>
</tbody>
</table>

Scleroderma and malignancy: an epidemiological study.

A K Rosenthal, J K McLaughlin, M S Linet and I Persson

*Ann Rheum Dis* 1993 52: 531-533
doi: 10.1136/ard.52.7.531

Updated information and services can be found at:
http://ard.bmj.com/content/52/7/531

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/